[Federal Register Volume 72, Number 12 (Friday, January 19, 2007)]
[Notices]
[Pages 2530-2531]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-720]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Clinical Laboratory Improvement Advisory Committee

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the following committee meeting.

    Name: Clinical Laboratory Improvement Advisory Committee 
(CLIAC). Web site: http://www.phppo.cdc.gov/CLIAC/default.aspx.
    Times and Dates: 8:30 a.m.-5 p.m., February 14, 2007; 8:30 a.m.-
3 p.m., February 15, 2007.

    Place: Omni Hotel at CNN Center, 100 CNN Center, Atlanta, 
Georgia 30303; Phone: (404) 659-0000, Fax: (404) 525-5050 (http://www.omnihotels.com/FindAHotel/AtlantaCNNCenter.aspx).
    Status: Open to the public, limited only by the space available. 
The meeting room accommodates approximately 100 people.
    Purpose: This committee is charged with providing scientific and 
technical advice and guidance to the Secretary of Health and Human 
Services, the Assistant Secretary for Health, and the Director, CDC, 
regarding the need for, and the nature of, revisions to the 
standards under which clinical laboratories are regulated, the 
impact on medical and laboratory practice of proposed revisions to 
the standards, and the modification of the standards to accommodate 
technological advances.
    Matters to be Discussed: The agenda will include updates from 
the CDC, the Centers for Medicare & Medicaid Services, and the Food 
and Drug Administration; discussion of the status of the ``Notice of 
Proposed Rulemaking'' for genetic testing; presentations and 
discussion concerning the future of health laboratory practice 
specifically focusing on simple testing in diverse sites; reports 
and discussions addressing the impact of the Morbidity and Mortality 
Weekly Report (MMWR) Publication of ``Good Laboratory Practices for 
Waived Testing Sites''; a report from the CLIAC Workgroup on ``The 
Impact of Rapid and Molecular Tests for Infectious Disease Agents on 
Public Health'' and discussion of the workgroup's proposals related 
to such; and presentations and discussion concerning rapid HIV 
testing. Agenda items are subject to change as priorities dictate.
    Providing Oral or Written Comments: It is the policy of CLIAC to 
accept written public comments and provide a brief period for oral 
public comments whenever possible.

[[Page 2531]]

    Oral Comments: In general, each individual or group requesting 
to make an oral presentation will be limited to a total time of five 
minutes (unless otherwise indicated). Speakers must also submit 
their comments in writing for inclusion in the meeting's summary 
report. To assure adequate time is scheduled for public comments, 
individuals or groups planning to make an oral presentation should, 
when possible, notify the contact person below at least one week 
prior to the meeting date.
    Written Comments: For individuals or groups unable to attend the 
meeting, CLIAC accepts written comments until the date of the 
meeting (unless otherwise stated). However, the comments should be 
received at least one week prior to the meeting date so that the 
comments may be made available to the committee for their 
consideration and public distribution. Written comments, one hard 
copy with original signature, should be provided to the contact 
person below. Written comments will be included in the meeting's 
summary report.
    Contact Person for Additional Information: Devery Howerton, 
Acting Chief, Laboratory Practice Standards Branch, Division Public 
Health Partnerships--Laboratory Systems, National Center for Health 
Marketing, Coordinating Center for Health Information and Service, 
CDC, 1600 Clifton Road, NE., Mailstop G-23, Atlanta, Georgia 30333; 
telephone (404) 718-1016; fax (404) 718-1080; or via e-mail at 
<a href="/cdn-cgi/l/email-protection#6c2824031b091e1803022c0f080f420b031a"><span class="__cf_email__" data-cfemail="2064684f574552544f4e604344430e474f56">[email protected]</span></a>.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register Notices pertaining 
to announcements of meetings and other committee management 
activities, for CDC and the Agency for Toxic Substances and Disease 
Registry.

    Dated: January 12, 2007.
Edward Schultz,
Acting Director, Management Analysis and Services Office, Centers for 
Disease Control and Prevention.
 [FR Doc. E7-720 Filed 1-18-07; 8:45 am]
BILLING CODE 4163-18-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>